Medical Director, FMR1 and Related Conditions Clinic, Kennedy Krieger Institute
Attending Pediatric Psychiatrist, Kennedy Krieger Institute
Co-Investigator/Physician, The Institute’s Center for Clinical Trials
Assistant Professor, Department of Psychiatry & Behavioral Sciences
Johns Hopkins University School of Medicine
Dr. Budimirovic received his medical training at the Belgrade University School of Medicine (Magna Cum Laude). After completing residencies in adult and child psychiatry at Harvard and New York University, Dr. Budimirovic was appointed assistant professor of psychiatry at Yale University School of Medicine. While at Yale, he cultivated a research interest in psychiatric disorders among children and adolescents. Over the last twelve years, Dr. Budimirovic has contributed to various research initiatives. Since his arrival at the Kennedy Krieger Institute in November 2004, he has significantly contributed to the expansion of clinical activities at the FMR1 and Related Conditions Clinic. He now serves as the Clinic’s Medical Director. Moreover, the Clinic, a founding member of the Fragile X Clinic & Research Consortium (FXCRC), has been selected as the site for two active multi-site clinical trials for which Dr. Budimirovic is the main co-investigator/physician:
- The phase III, pivotal clinical trial of STX209 (Arbaclofen) for the treatment of social withdrawal in adults, adolescents and children with FXS, sponsored by Seaside Therapeutics, Inc., and
- The phase II clinical trial of a mGluR5 antagonist (FRAGXIS NP 27936) for the treatment of social withdrawal in adults and pediatric populations with FXS, sponsored by Hoffmann-La Roche Ltd.
In addition, Dr. Budimirovic is also Principal Investigator on three projects: Fragile X Clinical and Research Cooperative Consortium Registry and Repository (JHH IRB NA_00028362); Fragile X Clinic Pharmacological Database (JHH IRB N_00069920), which will establish a database at the Institute for the purpose of future research; and Early Signs of Fragile X Syndrome (JHH IRB N_00072204), a multisite project which aims to identify early clinical signs of FXS for the purpose of facilitating an earlier genetic diagnosis of FXS.
Dr. Budimirovic is board certified by the American Board of Psychiatry and Neurology in the subspecialty of child and adolescent psychiatry. He is a member of the Directors of the FXCRC, and active member of the American Academy of Child and Adolescent Psychiatry.
Rebecca Hinton
FMR1 and Related Conditions Clinic Research Coordinator
Center for Genetic Disorders of Cognition & Behavior
Kennedy Krieger Institute
Becky received her BS in psychology from the University of Maryland in May 2009, and expects to receive her MS in clinical psychology from Loyola University Maryland in May 2012. She began working in the Center for Genetic Disorders of Cognition & Behavior as a Research and Clinic Coordinator in September of 2011. She is currently involved with managing the FMR1 and Related Conditions Clinic, as well as coordinating the Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome.